Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with marked variation in its clinical presentation. Juvenile-onset SLE (jSLE) exhibits an aggressive clinical phenotype and severe complications. Dysregulated expression of microRNAs (miRs) in immune cells from patients with SLE has been found. We aim to evaluate the association of miR-125a with the clinical and laboratory characteristics, disease activity and inflammatory cytokines of jSLE patients.
Methods
60 jSLE patients and 25 normal controls were involved in the study. The expression pattern of miR-125a was determined in plasma of all subjects using qRT-PCR. In addition, plasma levels of IL-17 and IFN-γ were examined using ELISA. The correlation of miR-125a expression with the clinical manifestations and disease activity of jSLE patients was analyzed. Also, its association with the inflammatory cytokines was investigated in jSLE patients.
Results
Our findings showed that miR-125a expression levels were significantly reduced in jSLE patients compared to normal controls (p < 0.01) and these expression levels differed based on the clinical variability of patients. In addition, plasma levels of IL-17 and IFN-γ in jSLE patients were significantly higher than healthy controls (p < 0.01). Finally, miR-125a expression had significant negative associations with each of SLEDAI-2K (p < 0.01), SLICC (p < 0.01), ESR (p < 0.05), proteinuria (p < 0.01) and IL-17 levels (p < 0.01) in jSLE patients.
Conclusion
Our findings postulate that miR-125a could act as a candidate therapeutic target for its possible regulation of inflammation in jSLE patients.
BatuEDKoşukcuCTaşkıranE, et al.
Whole exome sequencing in early-onset systemic lupus erythematosus. J Rheumatol2018;
45: 1671–1679.
2.
Demirkaya E, Sahin S, Romano M, Zhou Q, Aksentijevich I. New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond. J Clin Med 2020; 9(3): 712.
3.
TuckerLBUribeAGFernándezM, et al.
Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus2008;
17: 314–322.
4.
WenderferSERuthNMBrunnerHI.Advances in the care of children with lupus nephritis. Pediatr Res2017;
81: 406–414.
5.
QuinlanCMarksSDTullusK.Why are kids with lupus at an increased risk of cardiovascular disease?Pediatr Nephrol2016;
31: 861–883.
6.
HusakovaM.MicroRNAs in the key events of systemic lupus erythematosus pathogenesis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub2016;
160: 327–342.
7.
BartelDP.MicroRNAs: genomics, biogenesis, mechanism, and function. Cell2004;
116: 281–297.
8.
Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee SS. Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine. Mol Ther Nucleic Acids 2017; 8: 132–143.
9.
LeXYuXShenN.Novel insights of microRNAs in the development of systemic lupus erythematosus. Curr Opin Rheumatol2017;
29: 450–457.
10.
StypińskaBParadowska-GoryckaA.Cytokines and microRNAs as candidate biomarkers for systemic lupus erythematosus. Int J Mol Sci2015;
16: 24194–24218.
11.
SimpsonLJAnselKM.MicroRNA regulation of lymphocyte tolerance and autoimmunity. J Clin Invest2015;
125: 2242–2249.
12.
Lai NS, Koo M, Yu CL, Lu MC. Immunopathogenesis of systemic lupus erythematosus and rheumatoid arthritis: the role of aberrant expression of non-coding RNAs in T cells. Clin Exp Immunol 2017; 187(3): 327–336.
13.
ZanHTatCCasaliP.MicroRNAs in lupus. Autoimmunity2014;
47: 272–285.
14.
YinHSunYWangX, et al.
Progress on the relationship between miR-125 family and tumorigenesis. Exp Cell Res2015;
339: 252–260.
15.
PanWZhuSDaiD, et al.
MiR-125a targets effector programs to stabilize treg-mediated immune homeostasis. Nat Commun2015;
6: 7096.
16.
Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9(8): 589–93.
17.
BaechlerECBatliwallaFMKarypisG, et al.
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A2003;
100: 2610–2615.
18.
AnolikJHAringerM.New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol2005;
19: 859–878.
19.
ZhouHHuBHuangN, et al.
Aberrant T cell subsets and cytokines expression profile in systemic lupus erythematosus. Clin Rheumatol2018;
37: 2405–2413.
20.
GuoCZhouMZhaoS, et al.
Innate lymphoid cell disturbance with increase in ILC1 in systemic lupus erythematosus. Clin Immunol2019;
202: 49–58.
21.
PetriMOrbaiAMAlarcónGS, et al.
Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012;
64: 2677–2686.
Abdel Raouf H, Kholoussi NM, Eissa E, El Nady HG, Fayed DB, Abdelkawy RFM. MicroRNAs as Immune Regulators of Inflammation in Children with Epilepsy. Int J Mol Cell Med 2020; 9(3): 188–197.
24.
ElnadyHGAbdelmoneamNEissaE, et al.
MicroRNAs as potential biomarkers for childhood epilepsy. Open Access Maced J Med Sci2019;
7: 3965–3969.
De Laet C, Goyens P, Christophe C, Ferster A, Mascart F, Dan B. Phenotypic overlap between infantile systemic lupus erythematosus and Aicardi-Goutières syndrome. Neuropediatrics 2005; 36(6): 399–402.
27.
MehtaABaltimoreD.MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol2016;
16: 279–294.
28.
ZhaiPFWangFSuR, et al.
The regulatory roles of microRNA-146b-5p and its target platelet-derived growth factor receptor α (PDGFRA) in erythropoiesis and megakaryocytopoiesis. J Biol Chem2014;
289: 22600–22613.
29.
Marques-Rocha JL, Samblas M, Milagro FI, Bressan J, Martínez JA, Marti A. Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J 2015; 29(9): 3595–3611.
30.
PengHLiuYTianJ, et al.
Decreased expression of microRNA-125a-3p upregulates interleukin-23 receptor in patients with Hashimoto's thyroiditis. Immunol Res2015;
62: 129–136.
31.
Tahamtan A, Teymoori-Rad M, Nakstad B, Salimi V. Anti-Inflammatory MicroRNAs and Their Potential for Inflammatory Diseases Treatment. Front Immunol 2018; 9: 1377.
32.
MurataKFuruMYoshitomiH, et al.
Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. PLoS One2013;
8: e69118.
33.
HortuHOKaracaESozeriB, et al.
Evaluation of the effects of miRNAs in Familial Mediterranean Fever. Clin Rheumatol2019;
38: 635–643.
34.
Balci-Peynircioglu B, Akkaya-Ulum YZ, Akbaba TH, Tavukcuoglu Z. Potential of miRNAs to predict and treat inflammation from the perspective of Familial Mediterranean Fever. Inflamm Res 2019; 68(11): 905–913.
35.
Sun CM, Wu J, Zhang H, Shi G, Chen ZT. Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn’s disease. World J Gastroenterol 2017; 23(44): 7888–7898.
36.
Liu Q, Wang L, Yan G, Zhang W, Huan Z, Li J. MiR-125a-5p Alleviates Dysfunction and Inflammation of Pentylenetetrazol- induced Epilepsy Through Targeting Calmodulin-dependent Protein Kinase IV (CAMK4). Curr Neurovasc Res 2019; 16(4): 365–372.
37.
ZhaoXTangYQuB, et al.
MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum2010;
62: 3425–3435.
38.
SmithSWuPWSeoJJ, et al.
IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. JCI Insight2018;
3: e120798.
39.
LiHDingG.Elevated serum inflammatory cytokines in lupus nephritis patients, in association with promoted hsa-miR-125a. Clin Lab2016;
62: 631–638.
40.
Su YJ, Lin IC, Wang L, Lu CH, Huang YL, Kuo HC. Next generation sequencing identifies miRNA-based biomarker panel for lupus nephritis. Oncotarget 2018; 9(46): 27911–27919.
41.
AbulabanKMFallNNunnaR, et al.
Relationship of cell-free urine MicroRNA with lupus nephritis in children. Pediatr Rheumatol2016;
14: 4.
42.
Wen Z, Xu L, Xu W, Yin Z, Gao X, Xiong S. Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS One 2013; 8(3): e58161.
43.
Rana A, Minz RW, Aggarwal R, Anand S, Pasricha N, Singh S. Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 2012; 21(10): 1105–1112.
44.
GenoveseMCDurezPRichardsHB, et al.
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis2013;
72: 863–869.
45.
Becker-Merok A, Østli-Eilersten G, Lester S, Nossent J. Circulating interferon-α2 levels are increased in the majority of patients with systemic lupus erythematosus and are associated with disease activity and multiple cytokine activation. Lupus 2013; 22(2): 155–163.
46.
OkeVGunnarssonIDorschnerJ, et al.
High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther2019;
21: 107.
47.
RoseTGrützkauAHirselandH, et al.
IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis2013;
72: 1639–1645.
48.
YangXOPanopoulosADNurievaR, et al.
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem2007;
282: 9358–9363.
49.
YeSZhuSFengL.LncRNA ANRIL/miR-125a axis exhibits potential as a biomarker for disease exacerbation, severity, and inflammation in bronchial asthma. J Clin Lab Anal2020;
34: e23092.
